Showing results (221-230 of 308) with videos related to
Sort By:
Pageof 31
JAMA Neurology|November 3, 2015
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons LearnedRobert A Hauser, Fabrizio Stocchi, Olivier Rascol, et al.Plos One|February 1, 2021
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.CNS Spectrums|October 22, 2025
VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative reviewAmita R Patel, Robert A Hauser, Leslie Citrome, et al.Movement Disorders Clinical Practice|April 18, 2023
Expert Consensus on the Use of On-Demand Treatments for OFF Episodes in Parkinson's Disease: A Modified Delphi PanelStuart H Isaacson, Madhureeta Achari, Roongroj Bhidayasiri, et al.Clinical Parkinsonism & Related Disorders|April 22, 2026
Opicapone in Parkinson's patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON studyOlga Klepitskaya, Peter A LeWitt, Camilla Kilbane, et al.Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.Journal of Parkinson'S Disease|May 14, 2019
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal TrialsRobert A Hauser, Daniel E Kremens, Lawrence W Elmer, et al.Clinical Pharmacokinetics|May 20, 2018
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of DyskinesiaRobert A Hauser, Rajesh Pahwa, William A Wargin, et al.Parkinsonism & Related Disorders|August 22, 2020
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment toolRoongroj Bhidayasiri, John M Kane, Karen P Frei, et al.Pageof 31